x

This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 




US court backs Myriad to patent genes linked to cancer

Click the thumbnails below to view our monthly newsletters.

lsipr-newsletter-may-2013-thumbnail.jpg

May 2013

Highlights:

  • BerGenBio's new approach to cancer target screening
  • Supreme Court to hear Medtronic case
  • Monsanto: Supreme Court rejects 'blame-the-bean' defence
  • Self-collision of European patent filings
lsipr-april-thumbnail.jpg

April 2013

Highlights:

  • Novo Nordisk’s IP strategy
  • OFT accuses GSK market abuse over pay-for-delay deals
  • Actavis eyes $100 million after settlement
  • Obviousness of DNA fragments in the post-Kubin era
lsipr-newsletter-march-2013.jpg

March 2013

Highlights:

  • India rejects Bayer plea over compulsory licence
  • AstraZeneca settles Crestor patent dispute
  • Twenty-one years of SPCs–a cause for celebration?
  • Confidence in the face of counterfeits
lsipr-feb-13-cover.jpg

February 2013

Highlights:

  • Australian court backs Myriad in gene patent dispute
  • B-MS loses Baraclude patent fight with Teva
  • Hub and spoke? Life sciences in Northern France
  • UK patent change paves way for pharma innovation

Myriad, BRCA, ACLU, Mayo v Prometheus, gene patents, US Court of Appeals

More on this story

ACLU files Supreme Court brief in Myriad case
29-01-2013

WIPR

Payment types accepted